Home / Market News / $CADL
fiscal.ai Corporate Catalyst Impact 55/100 ● neutral

Multiple Financial Institutions Update Ratings and Price Targets for Candel Therapeutics

Nov 16, 2026, 2:05 AM UTC · Primary ticker $CADL

Multiple financial institutions have updated their research coverage on Candel Therapeutics, maintaining 'Buy' ratings but adjusting price targets to a range of $11 to $19 per share. This indicates continued analyst confidence in the company's prospects, albeit with some recalibration of valuation expectations.

On November 14, 2026, several prominent financial institutions, including Bank of America and Stifel, updated their research on Candel Therapeutics. While all firms maintained their 'Buy' ratings, a positive signal for the company, they did adjust their price targets, which now span a range of $11 to $19 per share. This suggests that while analysts remain optimistic about Candel's long-term potential, there may be some nuanced shifts in their short-to-medium term valuation models or market outlook. For traders, this could imply a period of moderate volatility as the market digests these new price targets, but the overall 'Buy' consensus provides a supportive backdrop for the stock. The key opportunity lies in identifying whether the new price targets reflect a more realistic valuation or if there's still upside potential based on the underlying business fundamentals.

$CADL positive Analysts maintain 'Buy' ratings, indicating continued confidence.
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.